PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2016
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Goserelin; Letrozole; Tamoxifen
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 07 Sep 2016 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 07 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 03 Nov 2015 New source identified and integrated (ClinicalTrials.gov NCT02592083).